174 related articles for article (PubMed ID: 20460043)
1. [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
Xu Y; Wang JB; Ji SW; Zhang YG; Siqingtu NL; Zhao P; Guo HH; Li Y; Jiao J; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):259-62. PubMed ID: 20460043
[TBL] [Abstract][Full Text] [Related]
2. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
3. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Liang J; Han T; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
[TBL] [Abstract][Full Text] [Related]
4. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
[TBL] [Abstract][Full Text] [Related]
6. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
[TBL] [Abstract][Full Text] [Related]
7. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
[TBL] [Abstract][Full Text] [Related]
8. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
9. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
[TBL] [Abstract][Full Text] [Related]
10. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
Zeuzem S; Gane E; Liaw YF; Lim SG; DiBisceglie A; Buti M; Chutaputti A; Rasenack J; Hou J; O'Brien C; Nguyen TT; Jia J; Poynard T; Belanger B; Bao W; Naoumov NV
J Hepatol; 2009 Jul; 51(1):11-20. PubMed ID: 19345439
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
13. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
[TBL] [Abstract][Full Text] [Related]
14. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
[TBL] [Abstract][Full Text] [Related]
16. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
17. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Han GR; Cao MK; Zhao W; Jiang HX; Wang CM; Bai SF; Yue X; Wang GJ; Tang X; Fang ZX
J Hepatol; 2011 Dec; 55(6):1215-21. PubMed ID: 21703206
[TBL] [Abstract][Full Text] [Related]
18. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Piratvisuth T; Komolmit P; Tanwandee T; Sukeepaisarnjaroen W; Chan HL; Pessôa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Cheinquer H; Pathan R; Dong Y; Trylesinski A
PLoS One; 2013; 8(2):e54279. PubMed ID: 23390496
[TBL] [Abstract][Full Text] [Related]
19. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
20. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
